

Hetlioz LQ - (4 mg/mL ; Suspension)

| | | | |
|------------------------------|--|-----------------------------|---------------------|
| Generic Name | Tasimelteon | Innovator | Vanda pharma |
| Dosage | 4 mg/mL ; Suspension | Branded US Sales | Less Than \$1000 mn |
| Probable FTF | Less Than 5 | Known Para IV Filers | Less Than 5 |
| Other ANDA developers | None | Tentative Approvals | None |
| Final Approvals | None | Generic Launches | None |
| Indication | HETLIOZ is a melatonin receptor agonist. HETLIOZ LQ oral suspension is indicated for the treatment of: • Nighttime sleep disturbances in SMS in pediatric patients 3 years to 15 years of age. | | |
| Complexities | Yes | | |

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.